| Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer DJ Sargent, S Marsoni, G Monges, SN Thibodeau, R Labianca, ... Journal of clinical oncology 28 (20), 3219-3226, 2010 | 1883 | 2010 |
| Randomized trial of TAS-102 for refractory metastatic colorectal cancer RJ Mayer, E Van Cutsem, A Falcone, T Yoshino, R Garcia-Carbonero, ... New England Journal of Medicine 372 (20), 1909-1919, 2015 | 1549 | 2015 |
| Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial C Louvet, R Labianca, P Hammel, G Lledo, MG Zampino, T André, ... Journal of Clinical Oncology 23 (15), 3509-3516, 2005 | 1263 | 2005 |
| FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular … C Cremolini, F Loupakis, C Antoniotti, C Lupi, E Sensi, S Lonardi, S Mezi, ... The Lancet Oncology 16 (13), 1306-1315, 2015 | 1232 | 2015 |
| Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer F Loupakis, C Cremolini, G Masi, S Lonardi, V Zagonel, L Salvatore, ... New England Journal of Medicine 371 (17), 1609-1618, 2014 | 1192 | 2014 |
| Impact of follow-up testing on survival and health-related quality of life in breast cancer patients: a multicenter randomized controlled trial P Ghezzi, S Magnanini, M Rinaldini, F Berardi, G Di Biagio, F Testare, ... Jama 271 (20), 1587-1592, 1994 | 561 | 1994 |
| Association of obesity with survival outcomes in patients with cancer: a systematic review and meta-analysis F Petrelli, A Cortellini, A Indini, G Tomasello, M Ghidini, O Nigro, M Salati, ... JAMA network open 4 (3), e213520-e213520, 2021 | 367 | 2021 |
| Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study E Diaz-Rubio, J Sastre, A Zaniboni, R Labianca, H Cortes-Funes, ... Annals of Oncology 9 (1), 105-108, 1998 | 318 | 1998 |
| Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with … C Cremolini, C Antoniotti, D Rossini, S Lonardi, F Loupakis, F Pietrantonio, ... The Lancet Oncology 21 (4), 497-507, 2020 | 309 | 2020 |
| Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer M Bregni, A Dodero, J Peccatori, A Pescarollo, M Bernardi, I Sassi, ... Blood, The Journal of the American Society of Hematology 99 (11), 4234-4236, 2002 | 264 | 2002 |
| The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first … G Fucà, V Guarini, C Antoniotti, F Morano, R Moretto, S Corallo, ... British journal of cancer 123 (3), 403-409, 2020 | 232 | 2020 |
| Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results … C Cremolini, F Loupakis, C Antoniotti, S Lonardi, G Masi, L Salvatore, ... Annals of oncology 26 (6), 1188-1194, 2015 | 197 | 2015 |
| Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial S Cascinu, R Berardi, R Labianca, S Siena, A Falcone, E Aitini, S Barni, ... The lancet oncology 9 (1), 39-44, 2008 | 180 | 2008 |
| Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy M Scartozzi, I Bearzi, C Pierantoni, A Mandolesi, F Loupakis, A Zaniboni, ... Journal of clinical oncology 25 (25), 3930-3935, 2007 | 164 | 2007 |
| Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study E Van Cutsem, C Boni, J Tabernero, B Massuti, G Middleton, F Dane, ... Annals of Oncology 26 (1), 149-156, 2015 | 155 | 2015 |
| Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised ‘GISCAD’trial R Labianca, A Sobrero, L Isa, E Cortesi, S Barni, D Nicolella, M Aglietta, ... Annals of oncology 22 (5), 1236-1242, 2011 | 153 | 2011 |
| Microsatellite instability in patients with stage III colon cancer receiving fluoropyrimidine with or without oxaliplatin: an ACCENT pooled analysis of 12 adjuvant trials R Cohen, J Taieb, J Fiskum, G Yothers, R Goldberg, T Yoshino, S Alberts, ... Journal of Clinical Oncology 39 (6), 642-651, 2021 | 151 | 2021 |
| Regorafenib for patients with metastatic colorectal cancer who progressed after standard therapy: results of the large, single‐arm, open‐label phase IIIb CONSIGN study E Van Cutsem, E Martinelli, S Cascinu, A Sobrero, M Banzi, JF Seitz, ... The oncologist 24 (2), 185-192, 2019 | 147 | 2019 |
| A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinoma G Rosati, G Ambrosini, S Barni, B Andreoni, G Corradini, G Luchena, ... Annals of oncology 27 (2), 274-280, 2016 | 145 | 2016 |
| Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO E Dell’Aquila, C Cremolini, T Zeppola, S Lonardi, F Bergamo, G Masi, ... Annals of Oncology 29 (4), 924-930, 2018 | 138 | 2018 |